Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

15.29 -0.27 (-1.70%)
Streaming Delayed Price Updated: 10:02 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Keros Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns. 
Via Benzinga
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal. 
Via Benzinga
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control. 
Via Benzinga
Analyst Expectations For Keros Therapeutics's Future
 
Via Benzinga
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
 
Via Benzinga
Where Keros Therapeutics Stands With Analysts
 
Via Benzinga
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control... 
Via Stocktwits
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
 
Via Benzinga
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
 
Via Benzinga
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
 
Via Benzinga
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
 
Via Benzinga
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
 
Via Benzinga
Topics Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
 
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
 
Via Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025. 
Via Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug. 
Via Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.